Massachusetts headquartered Biogen Inc.'s shares saw a slight drop of 0.41%, finishing Tuesday's trading session at $297.79. A total volume of 1.41 million shares was traded. In the last one month and since the start of this year, the stock has advanced 2.85% and 5.01%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 0.75% and 4.50%, respectively. Moreover, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders, have a Relative Strength Index (RSI) of 54.81.
On December 29th, 2016, research firm Raymond James reiterated its 'Strong Buy' rating on the Company's stock with an increase of the target price from $375 a share to $386 a share.
On January 05th, 2017, Amunix Operating Inc. announced that Biogen has exercised its option to enter into an exclusive, worldwide license agreement to develop and commercialize a novel, recombinant Factor IX product candidate that incorporates Amunix' XTEN technology to provide extended half-life. The agreement is part of Biogen's hemophilia business, which is expected to launch as Bioverativ on February 01st, 2017 as an independent, public company focused on the discovery, research, development and commercialization of treatments for hemophilia and other rare blood disorders. See our free and comprehensive research report on BIIB at:
On Tuesday, shares in Massachusetts headquartered Alnylam Pharmaceuticals Inc. recorded a trading volume of 775,546 shares, and ended the session 2.78% higher at $44.71. The stock has gained 9.56% in the last one month, 25.87% over the previous three months, and 19.42% on an YTD basis. The Company's shares are trading 6.82% above their 50-day moving average. Furthermore, shares of Alnylam Pharma, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have an RSI of 59.63.
On December 19th, 2016, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $89 a share to $69 a share.
On January 03rd, 2017, Alnylam announced that David-Alexandre "DA" Gros, M.D., Senior Vice President and Chief Business Officer, plans to leave the Company for personal reasons. His resignation will be effective January 06th, 2017. Additionally, the Company announced the promotion of Pushkal Garg, M.D., Senior Vice President, Clinical Development, to the role of Chief Medical Officer. ALNY free research report PDF is just a click away at:
Shares in Washington headquartered Cascadian Therapeutics Inc. closed at $4.77, dropping 4.02% from the last trading session. The stock recorded a trading volume of 99,969 shares. The Company's shares have gained 10.67% since the start of this year, and are trading 16.04% below their 50-day moving average. Additionally, shares of Cascadian Therapeutics, which engages in the research and development of therapeutic products for the treatment of cancer, have an RSI of 42.52.
On January 04th, 2017, Cascadian announced the appointment of Marc L. Lesnick, Ph.D., as Senior Vice President, Regulatory Affairs and Quality. He will lead the development of global regulatory strategy and quality processes, including advancing the Company's lead development program, tucatinib, through planned global regulatory processes to potential registration. Dr. Lesnick will report to Scott Myers, President and CEO of Cascadian. Sign up for your complimentary report on CASC at:
At the closing bell yesterday, shares in Pennsylvania-based Marinus Pharmaceuticals Inc. ended 0.88% lower at $1.12. A total volume of 1.08 million shares was traded, which was above their three months average volume of 753,840 shares. The stock has advanced 19.15% in the last one month and 10.89% on an YTD basis. The Company's shares are trading above their 50-day moving average by 7.09%. Furthermore, shares of Marinus Pharma, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, have an RSI of 62.49.
On January 03rd, 2017, Marinus Pharmaceuticals announced that the US Food and Drug Administration has granted Orphan Drug Designation to its CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome. Register for free on Stock-Callers.com and download the latest research report on MRNS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA